---
title: Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy
  + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
date: '2023-08-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37581611/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230815180933&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The findings indicate that the novel SBRT + LDRT + sintilimab
  therapy is safe and promising in patients with PD-L1-positive, driver gene-negative
  primary metastatic ...'
disable_comments: true
---
CONCLUSIONS: The findings indicate that the novel SBRT + LDRT + sintilimab therapy is safe and promising in patients with PD-L1-positive, driver gene-negative primary metastatic ...